CalcMyPeptide
Khavinson BioregulatorAlso known as: Bonothyrk A-21, Parathyroid Cytomax, A-21 Bioregulator

Bonothyrk

Khavinson A-21 natural peptide complex derived from parathyroid gland tissue — supports calcium homeostasis, bone mineral density, and parathyroid hormone (PTH) regulation.

Half-Life
~30 minutes (estimated)
Dose Range
1-2 capsules/day
Frequency
1-2× daily for 10-30 day cycles
Vial Sizes
N/A (oral)

Chemical Profile

Formula
Polypeptide extract (Parathyroid gland tissue, <5 kDa)
Molecular Wt
Mixture (<5 kDa, short-chain di- and tripeptides)
Half-Life
Variable (oral peptides absorbed via GI tract)
Bioavailability
Oral capsules (10 mg active peptides per capsule)
CAS Number
N/A (biological extract, not a single compound)
PubChem ID
N/A
Developer
Prof. Vladimir Khavinson & St. Petersburg Institute of Bioregulation
Year Developed
1980s (military-funded research, declassified 1990s)

Mechanism of Action

Bonothyrk (A-21) is a natural Cytomax — a purified polypeptide complex extracted from the parathyroid glands of young calves using Professor Vladimir Khavinson's patented low-temperature filtration method. The resulting short-chain peptides (under 5 kDa) act as tissue-specific epigenetic regulators for the parathyroid chief cells. **The Parathyroid's Critical Role** Your four parathyroid glands, each roughly the size of a grain of rice tucked behind your thyroid, are among the most physiologically critical structures in the body. Their one job: maintaining blood calcium and phosphate within extremely narrow bounds essential for cardiac function, nerve signaling, muscle contraction, and skeletal integrity. They do this via Parathyroid Hormone (PTH) — the master calcium regulator. When calcium drops, PTH rises to pull calcium from bone, increase kidney reabsorption, and activate Vitamin D (which then drives intestinal calcium absorption). When calcium is adequate, PTH falls. This feedback loop is extraordinarily precise. When it fails — through aging, vitamin D deficiency, or glandular dysfunction — cascading consequences follow. **Age-Related Parathyroid Dysfunction** As we age, two problematic patterns emerge: 1. **Secondary hyperparathyroidism** — chronically elevated PTH (often from Vitamin D deficiency) continuously leaches calcium from bone, driving osteoporosis, fracture risk, cardiovascular calcification, and kidney strain. 2. **Hypoparathyroidism** — inadequate PTH from glandular atrophy leads to hypocalcemia, severe muscle cramping, cardiac arrhythmias, and neurological symptoms. Bonothyrk addresses this by restoring healthy parathyroid chief cell function at the gene expression level — not by providing PTH itself, but by helping the glands produce the right amount autonomously. **Mechanism of Action** Bonothyrk's peptides penetrate parathyroid chief cell nuclei, binding to chromatin to unwind silenced gene regions and restore the transcriptional programs governing PTH synthesis, calcium-sensing receptor (CaSR) expression, and phosphate homeostasis. This epigenetic restoration is the hallmark of all Khavinson Cytomaxes — it does not override the body's feedback loops but restores the gland's own capacity to self-regulate. **Skeletal System Integration** Bonothyrk is specifically listed in Khavinson's locomotor apparatus stack (A-4 Sigumir + A-3 Ventfort + A-6 Vladonix + **A-21 Bonothyrk**), recognizing that bone health requires healthy cartilage AND healthy calcium regulation simultaneously. Sigumir rebuilds bone/cartilage tissue; Bonothyrk ensures the PTH-calcium axis that mineralizes that tissue is properly regulated.

Source: PMID: 12677266

Dosing Protocol

Typical Dose1-2 capsules/day
Frequency1-2× daily for 10-30 day cycles
Half-Life~30 minutes (estimated)

Dosing Protocols

Mini-Course / General Preventive (1 box)

Dose
2 capsules (20 mg)
Frequency
Once daily for 10 days (20 caps total = 1 box)
Note: Per Vita-Stream/Khavinson protocol: standard mini-course. Repeat every 6 months for general skeletal and calcium support. Take 30 minutes before meals. A 60-cap box extends this to a full 30-day course at 2 caps/day.

Full Monthly Course (ages 40–50)

Dose
2 capsules (20 mg)
Frequency
Twice daily for 30 days (120 caps total = 2× 60-cap boxes)
Note: Full 30-day bi-annual course from age 40–45. After 50, consider 3 courses/year. Pairs strongly with Sigumir (A-4) for comprehensive skeletal support. Ensure adequate Vitamin D3 + K2 baseline. Take 30 minutes before meals (morning + evening).

Intensive / High-Need Protocol

Dose
2 capsules (20 mg)
Frequency
Twice daily, repeated monthly as needed
Note: For diagnosed secondary hyperparathyroidism, significant osteoporosis, or post-surgical hypoparathyroidism support. Physician supervision strongly recommended. Combine with Ventfort (A-3) for vascular protection and Vladonix (A-6) for immune support. Maximum: 4 capsules/day (40 mg).

Administration

Route
Oral capsules (available in 20-cap and 60-cap boxes)
Timing
30 minutes before meals. Standard: 2 caps once daily. Intensive: 2 caps morning + 2 caps evening.
Fasting Required?
Yes — inject on an empty stomach

Expected Timeline

Days 1–7
Peptides begin binding to parathyroid chief cell chromatin; initial restoration of calcium-sensing receptor (CaSR) expression underway.
Weeks 2–4 (during course)
Normalization of PTH synthesis capacity. Users report reduced muscle cramping and improved energy if hypocalcemia was contributing to symptoms.
Months 1–3 (post-course)
Peak benefit period for calcium homeostasis restoration. Bone mineral density improvements take longer — expect to see DEXA improvements at 6–12 months when combined with Sigumir and D3/K2.
Months 4–6
Long-lasting epigenetic changes persist. PTH self-regulation improved. Skeletal system benefits accumulate with repeated courses.

Who Is It For?

Parathyroid Health & PTH Regulation

High

Primary target tissue. Restores age-suppressed parathyroid chief cell function for proper PTH secretion and calcium/phosphate balance.

Bone Mineral Density & Osteoporosis Prevention

High

Dysregulated PTH is a primary driver of bone loss. Bonothyrk addresses the hormonal root cause when paired with Sigumir for structural bone support.

Muscle Cramping & Neuromuscular Function

Moderate

Low calcium (from parathyroid dysfunction) causes severe muscle cramps and weakness. Bonothyrk supports the calcium regulation that prevents this.

Cardiovascular Protection

Moderate

Chronic elevated PTH promotes vascular calcification and cardiac hypertrophy. Normalizing PTH is cardioprotective. Pairs well with Ventfort (A-3).

Kidney Health

Moderate

Excess PTH increases renal calcium reabsorption stress and kidney stone risk. PTH normalization reduces this burden.

Aging / Longevity Protocol

High

Essential component of the Khavinson locomotor stack. Calcium dysregulation accelerates aging across multiple systems; Bonothyrk addresses this upstream.

Safety & Considerations

Bonothyrk is a natural glandular Cytomax with a 40+ year safety record in Russian clinical practice. It contains no actual PTH hormone and no synthetic analogs. The strict <5 kDa molecular weight filtration removes DNA fragments, prions, and immunogenic material. Important: Because PTH regulation is critical to cardiac and neuromuscular function, individuals with diagnosed parathyroid disorders (hyperparathyroidism, hypoparathyroidism) should use Bonothyrk under physician supervision with regular calcium/PTH blood monitoring. Contraindications per manufacturer: individual intolerance of components, pregnancy, and lactation. Drug interactions: No known direct interactions, but inform your physician if you are on calcium supplements, bisphosphonates, cinacalcet, vitamin D analogs, or cardiac medications — all of which interact with calcium metabolism. Storage: Keep in a dry, dark place between +2°C and +25°C.

Dosing Quick Reference

Bonothyrk— Dosing Guide
Dose Range
1-2 capsules/day
Half-Life
~30 minutes (estimated)
Frequency
1-2× daily for 10-30 day cycles
Route
Oral
Khavinson Bioregulatorcalcmypeptide.com

Frequently Asked Questions

What is Bonothyrk A-21 and what does it do?▼
Bonothyrk (A-21) is a natural Cytomax peptide bioregulator derived from parathyroid gland tissue, developed by Prof. Vladimir Khavinson. It supports the structural and functional health of the parathyroid glands — the four tiny glands behind your thyroid that regulate blood calcium and phosphate levels. It works by restoring healthy parathyroid cell gene expression, helping the glands self-regulate PTH production correctly.
Does Bonothyrk contain parathyroid hormone (PTH)?▼
No. Bonothyrk contains short-chain peptides (<5 kDa) derived from parathyroid tissue, but the strict filtration process removes all actual hormones, DNA material, and immunogenic substances. It signals your own parathyroid glands to normalize PTH production — it does not replace PTH exogenously. This makes it fundamentally different from pharmaceutical PTH analogs like teriparatide.
How does Bonothyrk support bone health?▼
Chronically elevated PTH (secondary hyperparathyroidism — very common in aging adults with low Vitamin D) is one of the primary drivers of bone density loss. It continuously signals osteoclasts to resorb bone to liberate calcium into the blood. Bonothyrk aims to normalize PTH secretion, removing this constant bone-resorption signal. For full bone health, pair with Sigumir (A-4, cartilage/bone structural support) and ensure adequate Vitamin D3 + K2 intake.
Who might benefit most from Bonothyrk?▼
Ideal candidates include: (1) adults over 45–50 with low Vitamin D and suspected secondary hyperparathyroidism (confirmed by elevated PTH on bloodwork); (2) those with osteoporosis or low bone density; (3) individuals experiencing muscle cramping, weakness, or numbness that may relate to calcium dysregulation; (4) post-menopausal women (estrogen drop worsens calcium metabolism); (5) anyone on a comprehensive Khavinson anti-aging Cytomax stack targeting skeletal longevity.
What peptides pair well with Bonothyrk?▼
Per Khavinson's protocols: Sigumir (A-4) for structural bone and cartilage support, Ventfort (A-3) for blood vessel health and cardiovascular protection from PTH excess, and Vladonix (A-6) for immune axis support. This locomotor stack is specifically listed in Khavinson's clinical recommendations. You can safely combine up to 5 Cytomaxes simultaneously.
Should I monitor blood calcium or PTH levels while taking Bonothyrk?▼
For preventive use in healthy individuals, routine monitoring is not strictly required but provides useful baseline data. If you have a diagnosed parathyroid condition or take medications affecting calcium metabolism (bisphosphonates, calcitonin, diuretics, calcium channel blockers), physician supervision with regular calcium/PTH bloodwork is strongly recommended. Khavinson's research approach emphasizes objective laboratory measurement before and after peptide courses.

References

  1. Khavinson VKh “"Peptide bioregulators — a new class of geroprotectors".” Bulletin of Experimental Biology and Medicine (2002). PMID: 12677266
  2. Khavinson VKh, Anisimov VN “"Peptide regulation of aging".” Rejuvenation Research (2007). PMID: 17516852
  3. Khavinson VK et al. “"Short peptides: nature, biosynthesis, and properties".” Advances in Gerontology (2019). PMID: 30641757
  4. Khavinson VK, Morozov VG “"Regulatory peptides and the aging process".” Neuroendocrinology Letters (2003). PMID: 14618157

📚 Related Articles

Epitalon: The Science of Telomerase Activation, Khavinson's Legacy, and Longevity Peptides
14 min read • Longevity

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

Verified Sourcing

Vita-StreamEst. $65–$125
In Stock

Note: Using these localized purchase links applies the community discount automatically and supports CalcMyPeptide database maintenance.

← Back to Peptide Library